posted on 2016-01-14, 00:00authored byOuti Keinänen, Xiang-Guo Li, Naveen K. Chenna, Dave Lumen, Jennifer Ott, Carla F. M. Molthoff, Mirkka Sarparanta, Kerttuli Helariutta, Tapani Vuorinen, Albert
D. Windhorst, Anu J. Airaksinen
A new 18F-labeled tetrazine derivative was developed
aiming at optimal radiochemistry, fast reaction kinetics in inverse
electron-demand Diels–Alder cycloaddition (IEDDA), and favorable
pharmacokinetics for in vivo bioorthogonal chemistry. The radiolabeling
of the tetrazine was achieved in high yield, purity, and specific
activity under mild reaction conditions via conjugation with 5-[18F]fluoro-5-deoxyribose, providing a glycosylated tetrazine
derivative with low lipophilicity. The 18F-tetrazine showed
fast reaction kinetics toward the most commonly used dienophiles in
IEDDA reactions. It exhibited excellent chemical and enzymatic stability
in mouse plasma and in phosphate-buffered saline (pH 7.41). Biodistribution
in mice revealed favorable pharmacokinetics with major elimination
via urinary excretion. The results indicate that the glycosylated 18F-labeled tetrazine is an excellent candidate for in vivo
bioorthogonal chemistry applications in pretargeted PET imaging approaches.